Objective To explore the influence of age and gender on outpatient medication in patients with high cardiovascular risk type 2 diabetes and heart failure.Methods The information of patients with metformin,insu-lin,SGLT2i,sacubitril-valsartan and ARB drugs prescribed in the outpatient department of a tertiary hospital from April 2022 to November 2023 was retrieved and analyzed by age,gender and diagnosis.Results Prescriptions for ARB,sacu-bitril-valsartan,SGLT2i,metformin,and insulin were 15 103,8 403,2 120,1 541,and 607,respectively.In terms of gen-der,the proportion of male patients with all types of drug treatment was higher than that of female patients.Among them,the proportion of male and female patients treated with SGLT2i was 63.58％and 36.42％,and the proportion of male and female patients treated with ARB drugs was 53.66％and 46.34％,respectively.Compared with patients treated with metformin,insulin,sacubitril-valsartan and ARB,SGLT2i treatment had significantly more male patients than female pa-tients(P＜0.05).In terms of age,the proportion of patients aged 18 to 40 years was the lowest,and the proportion of patients aged 66 years and older was the highest(except for patients treated with ARB drugs).Compared to patients trea-ted with sacubitril-valsartan or ARB,SGLT2i treatment for patients aged＞40-＜66 years and 66 and above showed sig-nificantly more male than female patients.After limiting diagnoses to prescriptions containing heart disease,patients over 40 years of age treated with SGLT2i continued to present significantly more men than women compared with patients trea-ted with sacubitril-valsartan or ARB(P＜0.05).Conclusions In department of cardiology,the gender(female,older than 40 years)of patients may have been a barrier to receiving SGLT2i drug therapy.This may result in some female pa-tients not receiving further cardiovascular protection.
国家科技期刊平台
NSTL
万方数据
